Transkaryotic Therapies, Inc.

Transkaryotic Therapies, Inc. (TKT) is a biopharmaceutical company dedicated to the development and commercialization of products based on its three proprietary development platforms: Gene Activated™ proteins, Niche Protein™ products and Gene Therapy.
The Company’s gene activation technology is a proprietary approach to the large-scale production of therapeutic proteins which does not require the cloning of genes and their subsequent insertion into non-human cell lines. TKT’s Niche Protein product platform is based on protein replacement for the treatment of rare genetic diseases, a group of disorders characterized by the absence of certain metabolic enzymes. The Company’s Gene Therapy technology, known as Transkaryotic Therapy, is focused on the commercialization of non-viral ex-vivo gene therapy products for the long-term treatment of chronic protein deficiency states.

Activity:

- Manufacturing
- Research & Development

Product / Technology type(s) covered:

- Bio
- Enzymes
- Pharmaceuticals / Therapeutics
- Proteins
- Technology

Therapeutic targets:

- Genetics

Markets Covered

a. HeadQuarter:

b. Continent(s) active: North America , Europe

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: